Epidermal growth factor receptor (EGFR) plays an important role in the biology of CRC [185] and is being used as a target for therapeutic antibodies in CRC patients with unmutated KRAS genes, but not in those with KRAS gene mutations which cause resistance [186,187]. Here, EGFR is linked to colorectal carcinoma.